We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Kidney Biopsy Profiles Predict Delayed Graft Function

By LabMedica International staff writers
Posted on 28 Feb 2018
The probability of renal graft failure can be assessed for donor kidney biopsies through histological analyses; the potential for delayed graft function is not as easily determined by morphology alone, but could potentially be aided by molecular analysis.

A scientific team led by those at Harvard University Office of Technology Development (Cambridge, MA; USA) used donor renal biopsies for both histological assessments and gene expression analysis. More...
RNA was extracted from tissue and reverse transcribed to complementary DNA (cDNA), which was combined with primers designed for genes that were chosen based on literature review related to delayed graft function.

The scientists used quantitative real-time polymerase chain reaction (PCR) to perform gene expression analyses, comparing biopsies from 16 kidneys that showed primary function upon transplantation with those 16 exhibiting delayed graft function. Delayed graft function described the condition of a patient requiring dialysis within a week of transplantation. From the set of genes that the team selected for comparison between the two renal biopsy groups, there were four that showed increased expression within the delayed graft function biopsy samples.

One of the four genes expressed more highly in delayed graft function samples was annotated as a gene for matrix metallopeptidase 3 (MMP3; stromelysin 1, progelatinase), which are related to inflammation and immune response. The other three genes showing more expression with delayed graft function were categorized as related to metabolism, and they were annotated as retinol-binding protein 4, plasma (RBP4); cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4 (CYP3A4); and fatty acid binding protein 1, liver (FABP1). For delayed graft function samples, these four genes showed increased expression from about 2.5- to 4.0-fold each. In comparison, for samples with immediate function, expression of these four genes hovered around 1.0-fold, with some signals slightly below 1.0 or between 1.0- and 2.0-fold.

The authors concluded that the results of their study indicated a possible gene fingerprint, with potential to forecast likelihood of delayed graft function for donor renal tissue. They recommended further research to assess the value of this approach in conjunction with existing protocols. The study was presented at the Annual Cutting Edge of Transplantation (CEOT) Meeting held February 8-10, 2018. Phoenix, AZ, USA.

Related Links:
Harvard University Office of Technology Development


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.